208 related articles for article (PubMed ID: 26994865)
1. Implementation of the 2011 Reimbursement Act in Poland: Desired and undesired effects of the changes in reimbursement policy.
Kawalec P; Sagan A; Stawowczyk E; Kowalska-Bobko I; Mokrzycka A
Health Policy; 2016 Apr; 120(4):356-61. PubMed ID: 26994865
[TBL] [Abstract][Full Text] [Related]
2. [Impact Reimbursement Act on the pharmaceutical market in Poland].
Giermaziak W
Pol Merkur Lekarski; 2014 Apr; 36(214):270-3. PubMed ID: 24868902
[TBL] [Abstract][Full Text] [Related]
3. Drug Policy in Poland.
Jahnz-Różyk K; Kawalec P; Malinowski K; Czok K
Value Health Reg Issues; 2017 Sep; 13():23-26. PubMed ID: 29073983
[TBL] [Abstract][Full Text] [Related]
4. European healthcare policies for controlling drug expenditure.
Ess SM; Schneeweiss S; Szucs TD
Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
[TBL] [Abstract][Full Text] [Related]
5. [Risk sharing methods in middle income countries].
Inotai A; Kaló Z
Acta Pharm Hung; 2012; 82(1):43-52. PubMed ID: 22570986
[TBL] [Abstract][Full Text] [Related]
6. Drug Policy in Slovakia.
Bucek Psenkova M; Visnansky M; Mackovicova S; Tomek D
Value Health Reg Issues; 2017 Sep; 13():44-49. PubMed ID: 29073987
[TBL] [Abstract][Full Text] [Related]
7. Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria.
Vassileva M; Kamusheva M; Manova M; Savova A; Tachkov K; Petrova G
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):733-742. PubMed ID: 30900482
[No Abstract] [Full Text] [Related]
8. Restrictions on the reimbursement policy with regard to retail marketing of medicinal products in Poland.
Zimmermann A
Acta Pol Pharm; 2013; 70(2):339-43. PubMed ID: 23614291
[TBL] [Abstract][Full Text] [Related]
9. Drug Policy in Bulgaria.
Dimova A; Rohova M; Atanasova E; Kawalec P; Czok K
Value Health Reg Issues; 2017 Sep; 13():50-54. PubMed ID: 29073988
[TBL] [Abstract][Full Text] [Related]
10. Drug Policy in Latvia.
Silins J; Szkultecka-Dębek M
Value Health Reg Issues; 2017 Sep; 13():73-78. PubMed ID: 29073995
[TBL] [Abstract][Full Text] [Related]
11. How to Reduce Prescription Drug Prices: First, Do No Harm.
Atlas S
Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
[No Abstract] [Full Text] [Related]
12. Impact of patient outcomes and cost aspects on reimbursement recommendations in Poland in 2012-2014.
Malinowski KP; Kawalec P; Trąbka W
Health Policy; 2016 Nov; 120(11):1249-1255. PubMed ID: 27884491
[TBL] [Abstract][Full Text] [Related]
13. Drug pricing and reimbursement in France. Towards a new model?
Le Pen C
Pharmacoeconomics; 1996; 10 Suppl 2():26-36. PubMed ID: 10163433
[TBL] [Abstract][Full Text] [Related]
14. Drug Policy in Romania.
Radu CP; Pana BC; Furtunescu FL
Value Health Reg Issues; 2018 Sep; 16():28-32. PubMed ID: 29704726
[TBL] [Abstract][Full Text] [Related]
15. The 1996 pricing and reimbursement policy in The Netherlands.
de Vos CM
Pharmacoeconomics; 1996; 10 Suppl 2():75-80. PubMed ID: 10163439
[TBL] [Abstract][Full Text] [Related]
16. Pricing and reimbursement of pharmaceuticals in Sweden.
Jönsson B
Pharmacoeconomics; 1994; 6 Suppl 1():51-60. PubMed ID: 10172482
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical expenditure and therapeutic value of new medicines in Spain.
Darba J
Pharmacoeconomics; 2003; 21(16):1211-2. PubMed ID: 14594440
[No Abstract] [Full Text] [Related]
18. [Risk-sharing schemes: a new paradigm in adopting innovative pharmaceuticals].
Hammerman A; Greenberg D
Harefuah; 2012 Jun; 151(6):364-7, 376. PubMed ID: 22991869
[TBL] [Abstract][Full Text] [Related]
19. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002.
Andersson K; Petzold MG; Sonesson C; Lönnroth K; Carlsten A
Health Policy; 2006 Dec; 79(2-3):231-43. PubMed ID: 16473436
[TBL] [Abstract][Full Text] [Related]
20. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
